News & Press
Medtronic's adaptive DBS system receives CE mark in Europe
Parkinson's News Today1/15/2025·01/15/25🌐 Europe
Summary
Medtronic's BrainSense aDBS system received CE Mark approval, indicating it meets EU safety, health, and environmental protection requirements. The system automatically adjusts stimulation according to a patient's brain activity, unlike conventional DBS. The technology will be available in Europe in early 2025. The company has also applied for FDA approval.
Why it matters
CE Mark approval for adaptive DBS represents a paradigm shift from constant stimulation to personalized, brain-responsive therapy. The technology could reduce side effects and improve quality of life for Parkinson's patients by delivering stimulation only when needed based on real-time neural signals.
#Deep Brain Stimulation#CE Mark#Parkinson's#Europe#Neurostimulation
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in